Over the past 20 years, Glenn Gormley, M.D., Ph.D., rose to a high altitude in the world of big pharma drug development. There were stints at AstraZeneca and Merck capped by a role as global head of clinical development and medical affairs for Novartis.
Now, though, he's made the leap from top executive at big pharma to biotech entrepreneur, taking the top job at Gemin X Pharmaceuticals just weeks before a third venture round reaped $38 million, bringing the company to more than $90 million in total money raised as it heads through the mid-stage point on its lead therapy. Article